Background The content validity (appropriateness and acceptability) of patient‐reported
outcome (PRO) measures for scalp hair loss, eyebrow loss, eyelash loss, nail damage and …

Background Valid patient‐reported outcome (PRO) measures are required to evaluate
alopecia areata (AA) treatments. Objectives To develop a content‐valid and clinically …

To the Editor, Alopecia areata (AA) is commonly evaluated using the Severity of Alopecia
Tool (SALT), which assesses scalp surface coverage and hair density. However, the SALT …

Background Eyebrow and eyelash hair loss and nail damage—in addition to scalp hair loss—
are important signs/symptoms of alopecia areata (AA) to patients and deserve assessment …

Introduction The content validity and treatment success thresholds of clinical outcome
assessments (COAs) for alopecia areata (AA)—including the Alopecia Areata-Investigator …

Introduction Individuals with alopecia areata (AA) may experience significant impacts on
their health-related quality of life. The novel Alopecia Areata Patient Priority Outcomes …

Background Although alopecia areata (AA) greatly impacts patients' quality of life (QoL),
there is no adequate validation of AA‐targeted QoL surveys in clinical trials, hindering …

Meaningful patient input to understand disease experience and patient expectations for
improvement with treatment is essential for the selection and development of outcome …

1 Kimball AB, Kerdel F, Adams D et al. Adalimumab for the treatment of moderate to severe
hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med 2012; 157: 846–55. 2 …

Introduction Alopecia areata (AA) is an autoimmune disease characterized by hair loss.
Patients with AA experience a range of social and emotional impacts, and the lack of …